Xianju Pharmaceutical announced that it recently received the “Drug Registration Certificate” for betamethasone sodium phosphate injection approved and issued by the State Drug Administration. The specification of this drug is 1ml: 4mg, and the registered classification is a chemical class 3. It is mainly used for glucocorticoid therapy-related diseases, and the original drug has been marketed in many countries. This approval is conducive to enriching the company's product line and enhancing competitiveness. However, drug R&D, production, and sales are affected by factors such as policies and markets, and there is uncertainty, reminding investors to be aware of risks.

Xianju Pharmaceutical announced that it recently received the “Drug Registration Certificate” for betamethasone sodium phosphate injection approved and issued by the State Drug Administration. The specification of this drug is 1ml: 4mg, and the registered classification is a chemical class 3. It is mainly used for glucocorticoid therapy-related diseases, and the original drug has been marketed in many countries. This approval is conducive to enriching the company's product line and enhancing competitiveness. However, drug R&D, production, and sales are affected by factors such as policies and markets, and there is uncertainty, reminding investors to be aware of risks.